Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Example Scenario: An injection is administered during a diagnostic imaging appointment, and the payer bundles it into the imaging service
We do not minimise the importance of medical screening and proper injection technique
While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
Our human SMC contractility model is designed to bring clarity where it matters: Real-time monitoring of vascular tone Quantification of contractile responses Mechanistic understanding of compound effects Based on impedance measurements, the model captures dynamic changes in cell morphology and cytoskeleton, directly linked to contractility What this means for your R&D: Earlier detection of vasoactive effects Better ranking of compounds More confident decisions before moving to in vivo Because better data early means fewer surprises later
US$ 23.16
US$ 26.16
US$ 20.48
US$ 29.68
